Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka, 812-8582, Japan.
Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka, 812-8582, Japan.
Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.
CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of CD44v9 in patients with lung adenocarcinoma is unknown.
We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients' clinicopathological features.
The expression of CD44v9 in 193 of 268 (72.0%) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor (EGFR) gene. Multivariate logistic analysis revealed that CD44v9 expression was significantly associated with early-stage disease [odds ratio (OR) 0.29, 95% confidence interval (CI) 0.14-0.59; p < 0.001] and mutant EGFR (OR 2.53, 95% CI 1.06-6.04; p = 0.036). The percentage of CD44v9-positive tumors was higher in the earlier stages of disease; however, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression.
CD44v9 was highly expressed in EGFR-mutant tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression may play an important role in EGFR-mutant tumors.
CD44 异构体可作为癌症干细胞的标志物。CD44 变体 9（CD44v9）有助于抵抗活性氧，导致对放化疗的耐药性。然而，CD44v9 在肺腺癌患者中的意义尚不清楚。
我们使用免疫组织化学分析方法回顾性分析了 268 例手术切除的肺腺癌中 CD44v9 的表达，并研究了 CD44v9 表达与患者临床病理特征之间的关系。
在 268 例患者中，193 例（72.0%）患者的 CD44v9 表达与早期癌症、低级别肿瘤、无血管和胸膜侵犯以及表皮生长因子受体（EGFR）基因突变显著相关。多变量逻辑分析显示，CD44v9 表达与早期疾病显著相关[比值比（OR）0.29，95%置信区间（CI）0.14-0.59；p<0.001]和突变型 EGFR（OR 2.53，95%CI 1.06-6.04；p=0.036）。疾病早期阶段 CD44v9 阳性肿瘤的比例较高；然而，在疾病各阶段，CD44v9 阳性或阴性表达的患者的生存无显著差异。
CD44v9 在 EGFR 突变型肿瘤中高度表达，特别是在早期肺腺癌中，表明 CD44v9 表达可能在 EGFR 突变型肿瘤中发挥重要作用。
